ArticleBiochemistry2026
Development of a FRET-Based Assay for Human Neutral Sphingomyelinase 2.
Article in Biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Neutral sphingomyelinase 2 (nSMase2) is a membrane-bound enzyme that hydrolyzes sphingomyelin (SM) into ceramide and phosphocholine. By generating the bioactive lipid ceramide, nSMase2 plays a critical role in cell stress responses and in regulating exosomes that package and transfer pathogenic factors, including tau protein and amyloid β. Thus, nSMase2 has been implicated in Alzheimer's disease and other neurological disorders. However, current tools to measure nSMase2 activity are limited, in particular those that could be used in therapeutic development. Here we developed a high-throughput assay to measure human nSMase2 activity. The assay uses a sphingomyelin substrate analogue with a FRET donor and acceptor pair attached to the headgroup and acyl-chain, respectively. Using recombinant human nSMase2, we sensitively detected both wild-type and mutant activity and demonstrated inhibition by the known nSMase2 inhibitor GW4869. The assay captures the major hallmarks of nSMase2 regulation by anionic lipids and displays sensitivity capable of detecting nSMase2 activity from cell lysates. Together, this assay enables rapid screening of nSMase2 inhibitors to support future therapeutic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.